Analysis
High debt and free-falling stock: Netflix might need to revisit its business model
Netflix’s (NASDAQ: NFLX) stock ended the most recent session at the lowest level since the beginning of the...
Analysis
Expert equity analysis, earnings previews, and data-driven market research.
Latest Research
1,807 articles
Analysis
How to play AutoZone Q4 earnings results
AutoZone (NYSE: AZO), a leading retailer of automotive replacement parts, is scheduled to report fourth-quarter financial results on...
Analysis
Nike bets on favorable pricing, DTC prowess to drive Q1 growth
Sneaker maker Nike, Inc. (NYSE: NKE) is scheduled to report its first-quarter 2020 results on September 24 at...
Analysis
Looking for a fast-growth IPO stock? Datadog begins trading today
Thanks to the robust transition to cloud-based infrastructure, technology companies providing business process solutions have been faring exceptionally...
Analysis
Mastercard or Visa: Which stock is a better investment option?
There isn’t much of a choice when it comes to owing a credit card, but it is important...
Analysis
GameStop takes baby steps on the road to recovery
GameStop Corp. (NASDAQ: GME) stock has risen over 40% in the past month as investors believed the video...
ADVERTISEMENT
Analysis
Despite short-term concerns, Starbucks stock offers high returns
The coffee culture that permeates across America is becoming popular in other parts of the world also. To...
Analysis
Beyond the ongoing strike, General Motors faces some serious headwinds
Even as the strike called by United Auto Workers union and participated by around 50,000 workers against General...
Analysis
Shopify could be the next Amazon – here’s why
Last month, the shares of e-commerce firm Shopify (NYSE: SHOP) reached a new peak at the New York...
Analysis
Will AMD stock continue to rally amid competition worries?
Advanced Micro Devices (NASDAQ: AMD) stock has risen over 73% in the year so far as the demands...
Analysis
Three companies that are haunted by multiple lawsuits
Several companies have battled lawsuits from time to time for various reasons. However, sometimes companies face thousands of...
Analysis
Alexion Pharmaceuticals could still be a valuable addition to your portfolio
Biopharmaceutical firm Alexion Pharmaceuticals (NASDAQ: ALXN) has been going through a volatile phase lately. The company was expected...